Shares of Micro Therapeutics Inc., an Irvine medical device maker, shot up 43% to $6 in after-hours trading after the Food and Drug Administration approved its application to commercialize its Onyx system for treating disorders of the brain’s blood vessels.
Micro said it plans to immediately start selling Onyx.
Onyx is a liquid embolic material that transforms into a solid polymer cast that seals defective arteries and veins, shutting off blood flow and reducing the risk of rupture. Onyx is delivered to a patient’s brain through tiny catheters.
Micro said that Onyx has been under development since 1995, and distributed internationally since 2002 by its majority shareholder, Minnesota-based ev3 Inc., which just went public.
